Viatris Products Ltd, Arixtra solution for injection, pre-filled syringes defect

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines defect notification for Arixtra solution for injection, pre-filled syringes.

Viatris has informed the MHRA that they have received reports of brown discolouration and blockage in the needle of pre-filled syringes of Arixtra. This quality defect is related to oxidation of the syringe needle.

The defect occurrence is estimated to be very rare. As Arixtra is considered critical to the continued supply of this medication, it will remain available for prescribing and is not being recalled from the market.

There is advice for handling precautions before dispensing or administering Arixtra.

Further information and advice can be found on the MHRA website.